Dermoscopy in the diagnosis and management of non-melanoma skin cancers

Department of Dermatology, University of L'Aquila, via Vetoio-Coppito 2, 67100 L'Aquila, Italy.
European journal of dermatology : EJD 04/2012; 22(4):456-63. DOI: 10.1684/ejd.2012.1727
Source: PubMed


Over the past two decades, dermoscopy has remarkably enhanced the diagnostic accuracy of pigmented skin lesions and, more recently, of non-pigmented skin disorders, including skin cancers, inflammatory and infectious diseases. With respect to non-melanoma skin cancers (NMSC), dermoscopy is an effective diagnostic tool for the clinical assessment of basal cell carcinoma, Bowen's disease, actinic keratosis and squamous cell carcinoma. Besides its relevance for diagnostic purposes, further applications of dermoscopy in the management of NMSC have been suggested in the preoperative evaluation, in monitoring the outcome of topical, light-based or laser treatments and in the post-treatment follow-up. This article summarizes the dermoscopic diagnostic criteria of NMSC and provides a review of the published literature as well as of our own experience on the usefulness of dermoscopy in monitoring surgical and medical treatment of NMSC.

Download full-text


Available from: Ketty Peris, Oct 05, 2015
1 Follower
202 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pseudolymphomatous folliculitis (PLF), which clinically mimicks cutaneous lymphoma, is a rare manifestation of cutaneous pseudolymphoma and cutaneous lymphoid hyperplasia. Here, we report on a 45-year-old Japanese woman with PLF. Dermoscopy findings revealed prominent arborizing vessels with small perifollicular and follicular yellowish spots and follicular red dots. A biopsy specimen also revealed dense lymphocytes, especially CD1a+ cells, infiltrated around the hair follicles. Without any additional treatment, the patient's nodule rapidly decreased. The presented case suggests that typical dermoscopy findings could be a possible supportive tool for the diagnosis of PLF.
    Case Reports in Dermatology 07/2012; 4(2):154-7. DOI:10.1159/000341194
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract is missing (Letter).
    Acta Dermato-Venereologica 11/2012; 93(4). DOI:10.2340/00015555-1507 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actinic keratoses (AK) are considered a worldwide problem with continuously increasing incidence. They clinically presents as rough or scaly plaques and are histologically characterized by a proliferation of atypical keratinocytes limited to the epidermis. AK is considered as an early step in the continuum of transformation from normal skin to invasive squamous cell carcinoma (SCC). These lesions develop on a background of field cancerization in which chronically UV- damaged-areas have accumulated molecular changes, but remain clinically normal for prolonged periods. The presence of certain clinical features of AK, such as large size, ulceration, or bleeding, suggests an increased risk of disease progression. The risk is also increased by evidence of extensive solar damage, advanced age, and immune-suppression. Many treatment modalities are available, although recent developments have focused on the management of the whole actinically damaged field. In this regard, several topical drugs have been approved, differing in efficacy, side effects, application and cost. Research is continuing aiming in the development of the "ideal" treatment which combines high clearance rates with few side effects, short treatment duration and low costs. Herein, we aim to give an overview on current treatment modalities including their mechanism of action, application scheme and common side effects. Furthermore, recent patents in the field and future aspects are discussed in this review.
    Recent Patents on Inflammation & Allergy Drug Discovery 03/2013; 7(2). DOI:10.2174/1872213X11307020008
Show more